Hearing directly from patients is one of the most meaningful parts of my work as a physician
There have been studies showing GLP-1 medications improving cardiovascular health, cognitive health, [and] Recent research has also shown that GLP-1 drugs may be associated with improved breast cancer survival rates and reduced recurrence in people with obesity and related conditions
Several companies, like Regeneron, are working on muscle-sparing (or even gaining) drugs to pair up with GLP-1s
These drugs mimic the action of the natural GLP-1 hormone, which stimulates insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite
Based on patient reports and clinical observations: Onset (Week 2-4): Initial body aches may appear as the first gastrointestinal effects emerge
Clinicians also evaluate lab trends, medications, and weight-related complications